NYSEReal EstateReal Estate ServicesSnapshot 2026-07-23
Reading RFL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is in the biotech sector, focusing on developing treatments for rare diseases, but it is currently loss-making and facing weak financial performance.
The market seems to have priced in a cautious outlook, reflecting the company's current losses and weak recent performance compared to its peers. Expectations may hinge on future developments in its drug pipeline and broader sector trends.
Fundamentals are likely to remain under pressure in the near term due to ongoing losses and weak financial results. However, management's focus on key milestones, such as the NDA submission for Trappsol Cyclo, may provide some support if achieved.
The long-term thesis hinges on several factors, including the potential easing of interest rates by the Fed and the performance of sector bellwethers like CBRE, BEKE, and JLL. Positive developments in these areas could provide a favorable backdrop for RFL.
Over the next 1 to 3 years, RFL's trajectory will depend on successful execution of its management priorities and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The NDA submission is a key step toward commercializing Trappsol Cyclo for NPC. It can unlock significant value for the company.
Confirms:The company submits the NDA for Trappsol Cyclo to the FDA in the second half of 2026.
Disproves:The NDA submission is delayed beyond the second half of 2026.
Why it matters: Better earnings would show a turnaround for Rafael Holdings. It is currently losing money.
Confirms:Q2 earnings show a smaller loss than the previous quarter, indicating progress.
Disproves:Q2 earnings report shows a larger loss than the previous quarter, confirming ongoing issues.
Why it matters: If revenue growth in the real estate sector picks up, it could benefit Rafael Holdings.
Confirms:Real estate sector revenue growth is speeding up again. It is now above 4%.
Disproves:Sector revenue growth is slowing down. It remains below 4%.
